CJC + Ipamorelin

Combination: controlled human benefit not established.



Guide prepared November 13, 2026 · profile review dates retained

KEEP IN MIND Evidence applies to the studied formulation, route, population and outcome—not every product sharing a name.

01 What is it?

CJC-1295 and ipamorelin stimulate growth-hormone signaling through different receptors. Their pairing is an unapproved combination; a change in hormone levels does not establish better recovery, body composition or health. [1]

02 Potential benefits

Both can stimulate the growth-hormone/IGF-1 axis through different receptors. Small studies established pharmacodynamic activity for CJC-1295. A biologic response does not establish anti-aging, recovery, or body-composition benefit. [1]

03 Evidence & its limits

Evidence for each ingredient's hormone response does not establish the combined product's clinical benefit or long-term safety. CJC-1295 identity also matters: results for the studied long-acting compound cannot simply be assigned to products sold under loosely related names. [1]

04 Risks & unknowns

The combination lacks FDA approval and robust controlled outcome trials. GH/IGF-1 stimulation may relate to edema, joint symptoms, glucose changes, or other risks. Combined long-term safety, optimal formulation, and product quality remain uncertain; both are prohibited in sport. [1]

05 Status & scope

Their pairing is an unapproved combination; a change in hormone levels does not establish better recovery, body composition or health. The combination lacks FDA approval and robust controlled outcome trials. [1]

06 The question to ask

Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.

SOURCES / Tap a reference to open

[1] Full evidence record, references and review dates
[2] Ipamorelin 1998 paper
[3] CJC-1295 human study
[4] WADA prohibited list

Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.